Swedish MedTech company MYoroface expands – innovative medical treatment for reflux now launched across the entire Nordic region

MYoroface is the Swedish MedTech company behind the unique innovation IQoro which treats the underlying cause of acid reflux, heartburn and more. IQoro has now been launched across all Nordic markets. Through a farsighted long-term global expansion strategy, the company wants to eventually address the fifth of the world’s population that suffer from acid reflux.

MYoroface produces the patented neuromuscular medical device IQoro. This unique innovation is the result of over 20 years’ scientific clinical research and treats the underlying cause of conditions including acid reflux and heartburn. Until now the company’s main focus has been on the already established markets in Sweden and the UK. Now the company is expanding and has launched e-commerce sites for D2C (private consumers) across the whole Nordic region.

Intensive growth phase and global expansion

– We are in the middle of an intensive growth phase. New customers that previously had not shopped online have ventured out into the digital commerce world during the pandemic. This has caused our customer base to grow dramatically. With our continued expansion in Europe during the second half of 2021 we will achieve new sales success. Investment in growth is a part of our long-term strategy. A global expansion is the natural next step, says Ylvali Gerling, CEO and co-founder of MYoroface.

The underlying cause of reflux can be treated simply

It is estimated that more than 20% of the world’s adult population suffers from acid reflux, with heartburn, persistent dry cough and thick phlegm as the usual symptoms. Reflux is caused by a Hiatal hernia, which allows the neck of the stomach to intrude through weakened musculature in the diaphragm into the chest cavity and leak stomach acids up into the esophagus. This can be successfully treated through neuromuscular training with IQoro.

– Through our expansion we will be able to reach out to more that suffer from reflux-based problems. We want them to be able to treat the underlying cause of their problems. Not just reduce the effect of the symptoms with PPI and other medications – which carry the risk of serious side-effects when used long-term. To be able to give a billion people the possibility to improve their quality of life is what gives us the drive to continue to expand our operations internationally – Ylvali Gerling concludes.